Concord Drugs Ltd.
Snapshot View

29.90 +1.15 ▲4.0%

26 July 2021, 04:00:00 P.M.
Volume: 15,888

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.concorddrugs.in
Financial Indicators
Market Cap 22.96 Cr.
Earnings per share (EPS) 4.18 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 6.99 Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share 32.92 Trailing Twelve Months Ending 2021-03
Price to Book Value 0.89 Calculated using Price: 29.20
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.79 Cr. 7,861,750 Shares
FaceValue 10
Company Profile

Concord Drugs is a public limited company established in the year 1995. The company is one among selected few pharmaceutical companies in India with dedicated state of art WHO-GMP certified facility. The company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide its customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing. The company has manufacturing license issued by the Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.

Concord Drugs operates a state of the art, cGMP contract manufacturing Formulation-Fill-Finish facility, providing comprehensive pharmaceutical development and manufacturing services for drug products. Concord Drugs Limited has two manufacturing facilities built to comply with standards stipulated by Regulatory bodies.

Business area of the company:

Concord Drugs is engaged in developing new products Viz MUPS (Multiple Unit Pellet System), Sustained Release, Modified Release pellets with Innovative Drug Delivery Technologies by utilizing best and latest processing machinery.

Products

Concord Drugs offers products of international standards through innovations with foresight of its responsibility towards the Society at large:

  • Gastrointestinal Drug Pellets
  • Cardivascular Drug Pellets
  • Respiratory Drug Pellets
  • Pain Management Drug Pellets  
  • Anti Obesity Drug Pellets  
  • Anti Depressant Drug Pellets
  • Central Nerous System Drug Pellets  
  • Urological Drug Pellets
  • Anti - Microbial, Anti - Infective & Adjuvant Drug Pellets  
  • Taste Mask Drug Pellets/Powder 
  • Nutrition and Food Suppliment Drug Pellets
  • Anti Cholestrol Drug Pellets
  • Multi Unit Pellet System Drug Pellets (Mups) 

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+4.00%
1 Week
-3.24%
1 Month
-8.14%
3 Month
-22.84%
6 Month
+28.60%
1 Year
+105.50%
2 Year
+54.52%
5 Year
-53.50%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 16.85 8.85 2.72 5.37 12.32 0.94 1.69 1.92 1.41
Return on Capital Employed (%) 15.24 6.30 7.15 11.33 15.90 8.84 7.49 6.17 6.06
Return on Assets (%) 7.16 2.93 0.79 1.41 3.28 0.30 0.40 0.43 0.47

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 13 14 15 13 15 19 19 23 23
Non Curr. Liab. 5 12 12 13 17 7 6 4 4
Curr. Liab. 12 15 18 28 21 29 81 56 31
Minority Int.
Equity & Liab. 30 41 45 54 52 56 106 83 58
Non Curr. Assets 11 20 21 19 16 25 14 13 12
Curr. Assets 18 21 23 36 37 30 92 70 46
Misc. Exp. not W/O
Total Assets 30 41 45 54 52 56 106 83 58

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 28 28 34 40 51 57 52 48 51
Other Income 0 0 0 0 0 0 0 0
Total Income 28 28 34 40 51 58 52 48 51
Total Expenditure -25 -26 -31 -33 -42 -52 -47 -44 -48
PBIDT 3 2 3 7 8 6 5 4 3
Interest 0 -1 -2 -3 -3 -2 -2 -2 -2
Depreciation -1 -1 -1 -4 -3 -3 -2 -2 -1
Taxation -1 0 0 0 -1 0 0 0 0
Exceptional Items
PAT 2 1 0 1 2 0 0 0 0

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. -3 1 2 2 4 2 7 1 2
Cash Fr. Inv. -2 -10 -2 -1 0 -1 -2 0 -1
Cash Fr. Finan. 6 8 0 -1 -4 -4 -5 -1 -1
Net Change 0 -1 0 0 0 -3 0 0 0
Cash & Cash Eqvt 1 0 0 0 0 -3 0 0 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 42.78 42.78 42.78 42.78 42.78 42.78 42.78 44.38 44.38
Public 57.22 57.22 57.22 57.22 57.22 57.22 57.22 55.62 55.62
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 21 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Jyoti Goyal
Designation :- Company Secretary and Compliance Officer
Wed, 21 Jul 2021
Shareholding for the Period Ended June 30 2021
Concord Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Wed, 21 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulations 2018

Technical Scans View Details

Mon, 26 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 703.40 +1.4%
Divi's Laboratories Ltd. 130,349.05 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,411.25 -0.2%
Cipla Ltd. 76,675.40 950.55 +0.3%
Cadila Healthcare Ltd. 61,992.73 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,100.95 +4.7%
Aurobindo Pharma Ltd. 55,837.02 952.95 -1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.88 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 952.95 -1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 952.95 -1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%